Knowledge and attitude of Iraqi pharmacists in Baghdad community toward ‎adverse drug reactions monitoring

  • Samer Imad Mohammed Assistant Lecturer
  • Amna Fouad Abdul Al-razaq Pharmacist at Ministry of health -Iraq


Objectives:Adverse drug reactions (ADR‎s) can lead to many complications associated with the use of medications .In Iraq where a wide range of medications misused widely due to different reasons, the Iraqi pharmacovigilance program started out few years ago to collect information about adverse drugs reactions and since the success of this program depends on the effective participation of all medical staffs including pharmacists in this program. This study aimed to assess the knowledge, attitude, and degree of awareness of Iraqi pharmacists in Baghdad community toward adverse drugs reactions monitoring and pharmacovigilance program.

Methods: This study was a cross-sectional descriptive survey based on individual questionnairethat administered in the English language to a convenience sample of 150 pharmacists working in 3 colleges of pharmacy, 20 community pharmacies and 3 hospitals situated in different areas of Baghdad which are the capital of Iraq. The questionnaire consists of three parts that collect demographic data on the ‎participants and their knowledge, attitudes toward Pharmacovigilance‎. 

Results: Although about (62%) of pharmacists have observed ADRs in their practice‎ only half of the respondents have heard about the term pharmacovigilance, 48% were aware of the national PV program ‎‎.Moreover , (‎47.33%‎) of the respondents mentioned that ADRs associated with herbal ‎products should not be reported. Although ‎79% of the respondents thought that reporting ADRs is a pharmacist's duty nevertheless 82% of them  ‎thought that ADRs reporting in Iraq is not widely promoted by the relevant authority .The study showed a high tendency for participation in an adverse drug reaction  monitoring program. Interestingly,‎ 60% of respondents report that their workplace ‎doesn't encourage them for reporting ADRs, while 48% of respondents indicated that they don't ‎have enough time for reporting ADRs and 38% of them declared their fearing of facing ‎legal problem from that .  ‎

Conclusion: Iraqi pharmacists although have a high tendency in participation in ADR monitoring  program but have  a poor knowledge about pharmacovigilance practices; they lack ‎understanding of the details about the national PV system and ADRs ‎reporting process and may need more information on how ADRs ‎reporting are performed. 

Keywords: Knowledge, Attitudes, Adverse drug reactions, Pharmacovigilance.

Author Biography

Samer Imad Mohammed, Assistant Lecturer
Assistant lecturer in Department of clinical pharmacy-College of Pharmacy- Baghdad University


1. Griffin JP. The evolution of human medicines control from a national to an international perspective. Adverse Drug React Toxicol Rev 1998;17(1):19-50.
2. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 2000;356(9237):1255-9.
3. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.
4. Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 2000;34:1373-9.
5. Mouton JP, Mehta U, Parrish AG, Wilson DP, Stewart A, Njuguna CW, et al. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: A cross-sectional survey. Br J Clin Pharmacol 2015;80(4):818-26.
6. World Health Organization. WHO Policy Perspectives on Medicines. Looking at the Pharmacovigilance: Ensuring the Safe Use of Medicines. Geneva: WHO; 2004. Available from:
7. Feldschreiber P, Breckenridge A. After thalidomide - Do we have the right balance between public health and intellectual property. Rev Recent Clin Trials 2015;10(1):15-8.
8. Jacob D, Marrón B, Ehrlich J, Rutherford PA. Pharmacovigilance as a tool for safety and monitoring: A review of general issues and the specific challenges with end-stage renal failure patients. Drug Healthc Patient Saf 2013;5:105-12.
9. Venulet J. The drug monitoring programme. In: Drug Surveillance. Geneva: World Health Organization; 1994. p. 13-21.
10. World Health Organization. Safety of medicines: A guide to detecting and reporting adverse drug reactions: Why health professionals need to take action. In: Safety of Medicines: A Guide to Detecting and Reporting Adverse Drug Reactions: Why Health Professionals Need to Take Action. Geneva: WHO; 2002.
11. Jassim AM. In-home drug storage and self-medication with antimicrobial drugs in Basrah, Iraq. Oman Med J 2010;25(2):79-87.
12. Mohammed SI. Evaluation of analgesics use and misuse by Iraqi patients in Baghdad community. Asian J Pharm Clin Res 2016;9(1):303-7.
13. Alwan MH. Guidelines for Detecting & Reporting Adverse Drug Reactions in Iraq Individual Case Safety Reports, Iraqi Pharmacovigilance Center Version 1. Ministry of health, Iraq 2012.; 2012. Retrieved from [Last accessed on ???].
14. Khalili H, Mohebbi N, Hendoiee N, Keshtkar AA, Dashti-Khavidaki S. Improvement of knowledge, attitude and perception of healthcare workers about ADR, a pre- and post-clinical pharmacists’ interventional study. BMJ Open 2012;2(1):e000367.
15. van Grootheest AC, de Jong-van den Berg LT. The role of hospital and community pharmacists in pharmacovigilance. Res Social Adm Pharm 2005;1(1):126-33.
16. Alshakka M, Abdorabbo A, Basaleem H, Jha N, Alshammari T, Shankar PR. Knowledge, attitude beliefs and practices of community pharmacy dispensers in Aden, Yemen towards adverse drug reaction reporting. World J Pharm Sci 2015;3(10):2111-8.
17. Ahmad A, Patel I, Balkrishnan R, Mohanta GP, Manna PK. An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting: A pilot study. Perspect Clin Res 2013;4(4):204-10.
18. Toklu HZ, Uysal MK. The knowledge and attitude of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul. Pharm World Sci 2008;30(5):556-62.
19. Green CF, Mottram DR, Rowe PH, Pirmohamed M. Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. Br J Clin Pharmacol 2001;51(1):81-6.
20. van Grootheest AC, Mes K, de Jong-van den Berg LT. Attitudes of communitypharmacists in the Netherlands towards adverse drug reaction reporting. Int J Pharm Pract 2002;10:267-72.
21. Mahmoud MA, Alswaida Y, Alshammari T, Khan TM, Alrasheedy A, Hassali MA, et al. Community pharmacists’ knowledge, behaviors and experiences about adverse drug reaction reporting in Saudi Arabia. Saudi Pharm J 2014;22(5):411-8.
22. Gupta P, Udupa A. Adverse drug reaction reporting and pharmacovigilance: Knowledge, attitudes and perceptions amongst resident doctors. J Pharm Sci Res 2011;3(2):1064-9. 23. Desai CK, Iyer G, Panchal J, Shah S, Dikshit RK. An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital. Perspect Clin Res 2011;2(4):129-36.
24. Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol 2015;8(4):449-60.
25. Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol 2009;9:14.
26. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: A review of published literature and international experience. Br J Clin Pharmacol 2007;63(2):148-56.
27. van Hunsel F, Passier A, van Grootheest K. Comparing patients’ and healthcare professionals’ ADR reports after media attention: The broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol 2009;67(5):558-64.
325 Views | 272 Downloads
How to Cite
Mohammed, S. I., and A. F. Abdul Al-razaq. “Knowledge and Attitude of Iraqi Pharmacists in Baghdad Community Toward ‎adverse Drug Reactions Monitoring”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 4, Apr. 2017, pp. 219-22, doi:10.22159/ajpcr.2017.v10i4.16595.
Original Article(s)